Literature DB >> 20882367

Impact of intraventricular hemorrhage upon intracerebral hematoma expansion.

Michael Moussouttas1, Rishi Malhotra, Luis Fernandez, Mitchell Maltenfort, Melissa Holowecki, Jennifer Delgado, Nadine Lawson, Neeraj Badjatia.   

Abstract

BACKGROUND: The purpose of this study is to determine whether intraventricular hemorrhage (IVH) exerts a "decompressive" effect that limits intracerebral hemorrhage (ICH) enlargement.
METHODS: Retrospective review of patients with spontaneous supratentorial ICH diagnosed within 6 h of onset, who underwent follow-up head CT approximately 48 h later. Digital imaging analysis of CT scans was performed to compare hematoma volume changes between patients with and without IVH. Hemorrhage locations were classified as paraventricular (PV) or non-PV. Regression analyses were employed to identify predictors of IVH, hematoma expansion, and mortality.
RESULTS: Of the 70 patients included 57% developed IVH, 85% of which occurred before initial CT. 71% of PV hemorrhages developed IVH, all before initial CT, and 48% of non-PV hemorrhages developed IVH, 29% of which occurred after initial CT. IVH was associated with PV location (P = 0.04), and among IVH patients PV location was associated with early IVH (P = 0.003). Predictors of mortality included age (P = 0.037), initial hematoma volume (P < 0.04), absolute volume change (P = 0.01), and final hematoma volume (P < 0.001). Variables predicting IVH included PV location (P < 0.0001), larger initial hematoma volume (P = 0.002), and greater absolute volume increase (P = 0.01). Hematoma expansion was greatest for non-PV with IVH (P = 0.08), and graphic inspection suggested that ICH volume tended to decrease with PV location and increase with IVH. Final hematoma volume was associated with initial volume (P < 0.0001), non-PV location (P = 0.02), and IVH (P = 0.04).
CONCLUSIONS: IVH was not associated with less hematoma volume expansion, and for non-PV hemorrhages IVH was linked to greater volume increase.

Entities:  

Mesh:

Year:  2011        PMID: 20882367     DOI: 10.1007/s12028-010-9452-0

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  21 in total

1.  Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage.

Authors:  S M Davis; J Broderick; M Hennerici; N C Brun; M N Diringer; S A Mayer; K Begtrup; T Steiner
Journal:  Neurology       Date:  2006-04-25       Impact factor: 9.910

Review 2.  Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions.

Authors:  Thorsten Steiner; Jonathan Rosand; Michael Diringer
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

3.  Early hemorrhage growth in patients with intracerebral hemorrhage.

Authors:  T Brott; J Broderick; R Kothari; W Barsan; T Tomsick; L Sauerbeck; J Spilker; J Duldner; J Khoury
Journal:  Stroke       Date:  1997-01       Impact factor: 7.914

4.  Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates.

Authors:  Hagen B Huttner; Peter D Schellinger; Marius Hartmann; Martin Köhrmann; Eric Juettler; Johannes Wikner; Stephan Mueller; Uta Meyding-Lamade; Ralf Strobl; Ulrich Mansmann; Stefan Schwab; Thorsten Steiner
Journal:  Stroke       Date:  2006-05-04       Impact factor: 7.914

5.  Determinants of intracerebral hemorrhage growth: an exploratory analysis.

Authors:  Joseph P Broderick; Michael N Diringer; Michael D Hill; Nikolai C Brun; Stephan A Mayer; Thorsten Steiner; Brett E Skolnick; Stephen M Davis
Journal:  Stroke       Date:  2007-02-08       Impact factor: 7.914

6.  The ICH score: a simple, reliable grading scale for intracerebral hemorrhage.

Authors:  J C Hemphill; D C Bonovich; L Besmertis; G T Manley; S C Johnston
Journal:  Stroke       Date:  2001-04       Impact factor: 7.914

7.  Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group.

Authors:  Joseph Broderick; Sander Connolly; Edward Feldmann; Daniel Hanley; Carlos Kase; Derk Krieger; Marc Mayberg; Lewis Morgenstern; Christopher S Ogilvy; Paul Vespa; Mario Zuccarello
Journal:  Stroke       Date:  2007-05-03       Impact factor: 7.914

8.  Antihypertensive treatment of acute cerebral hemorrhage.

Authors: 
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

9.  Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry.

Authors:  Simona Sacco; Carmine Marini; Danilo Toni; Luigi Olivieri; Antonio Carolei
Journal:  Stroke       Date:  2008-11-26       Impact factor: 7.914

10.  Computer-assisted volumetric analysis compared with ABC/2 method for assessing warfarin-related intracranial hemorrhage volumes.

Authors:  William D Freeman; Kevin M Barrett; Joseph M Bestic; James F Meschia; Daniel F Broderick; Thomas G Brott
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

View more
  3 in total

1.  Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage.

Authors:  Michael Moussouttas
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

2.  The intraventricular-spot sign: prevalence, significance, and relation to hematoma expansion and outcomes.

Authors:  Omar Hussein; Khalid Sawalha; Mohammad Hamed; Ahmed Abd ElAzim; Lai Wei; Michel T Torbey; Archana Hinduja
Journal:  J Neurol       Date:  2018-07-16       Impact factor: 4.849

Review 3.  Prediction and observation of post-admission hematoma expansion in patients with intracerebral hemorrhage.

Authors:  Christian Ovesen; Inger Havsteen; Sverre Rosenbaum; Hanne Christensen
Journal:  Front Neurol       Date:  2014-09-29       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.